Bronchoscopic phototherapy at comparable dose rates: early results.
Photodynamic therapy is a recently introduced treatment for surface malignancies. Since January 1987, 10 patients with endobronchial neoplasms have had bronchoscopic photodynamic therapy at similar dose rates (400 mW/cm) for total atelectasis (2), carinal narrowing with respiratory insufficiency (2), or partial obstruction without collapse (4). Two patients underwent photodynamic therapy as a preliminary to immunotherapy. Histologies included endobronchial metastases (colon, ovary, melanoma, and sarcoma, 1 each; and renal cell, 3) and primary lung cancer (3). The 2 patients with total atelectasis had complete reexpansion after photodynamic therapy, which permitted eventual sleeve lobectomy in 1. Carinal narrowing was ameliorated in the 2 patients seen with inspiratory stridor, thereby permitting hospital discharge. Endoscopically resected fragments after photodynamic therapy exhibited avascular necrosis. These data support further controlled studies of photodynamic therapy by thoracic surgical oncologists to define its limitations as well as to improve and expand its efficacy as a palliative or surgical adjuvant.
Pass
H I
HI
Thoracic Oncology Section, National Cancer Institute, Bethesda, Maryland 20892.
Delaney
T
T
Smith
P D
PD
Bonner
R
R
Russo
A
A
D000328:Adult; D001984:Bronchial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D001999:Bronchoscopy; D017323:Dihematoporphyrin Ether; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006415:Hematoporphyrins / Q000627:therapeutic use; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods; D011829:Radiation Dosage
D006415:Hematoporphyrins; D017323:Dihematoporphyrin Ether